CONMED (CNMD)
Makes surgical devices for orthopedic and minimally invasive general procedures.
Something off on this page? Send us feedback.
Sells orthopedic and general-surgery devices, with product families spanning sports medicine, powered instruments, AirSeal insufflation, smoke evacuation, electrosurgery, and patient monitoring. Revenue is mostly recurring single-use products, with a meaningful international base and an active exit from gastroenterology.
Develops, manufactures, and sells surgical devices used in orthopedic surgery and general surgery. The portfolio includes sports-medicine implants and suture anchors, BioBrace soft-tissue repair, Hall powered instruments, AirSeal insufflation and access, Buffalo Filter smoke evacuation, electrosurgery, laparoscopic instruments, and patient-monitoring products.
Operates as one global segment while reporting the business through Orthopedic Surgery and General Surgery product lines. Sales are meaningfully international, and the model relies heavily on recurring single-use products alongside capital equipment.
Executes through procedure-specific product platforms and acquisitions that added Linvatec, SurgiQuest, Buffalo Filter, In2Bones, and Biorez. Current portfolio shape is affected by the exit from gastroenterology product lines, regulated medical-device markets, hospital purchasing cycles, and competition from larger medtech companies.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 13, 2026 | Wells Fargo | Target | Target: — | Target: $39 |
| Jul 8, 2026 | BMO Capital | Initiate | Rating: —Target: — | Target: $36 |
| Jun 29, 2026 | Bank of America Securities | Downgrade | Rating: — | |
| Jun 29, 2026 | B of A Securities | Downgrade | ||
| Mar 17, 2026 | Piper Sandler | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $37.3M · Total debt $834.2M · Total assets $2.30B · Shareholders' equity $1.04B
- Revenue
- $343.5M
- Operating income
- $36.4M
- Net income
- $23.1M
HistoryDividendAnnual yield
| Institutions | 115.42% | 34.57M shares | |
|---|---|---|---|
| 251 holders · as of Jun 30, 2026 | |||
| Insiders | 0.41% | 121.5K shares | |
| 16 holders · as of Sep 10, 2026 | |||
| Adds to | 115.83% | ||
29.95M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 115.83%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 16.10% | 4.82M | as of Jun 30, 2026 |
Earnest Partners LLCInstitution | 8.36% | 2.51M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 7.31% | 2.19M | as of Jun 30, 2026 |
Fuller & Thaler Asset Management, Inc.Institution | 5.27% | 1.58M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.73% | 1.42M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 21, 2025 | Richard Glaze | officer: Chief Information Officer | −257 | $41.21 |
| Nov 6, 2025 | Todd W. Garner | officer: Executive Vice President & CFO | −3,500 | $43.00 |
- Stryker
Broad overlap in orthopedics, instruments, and endoscopy
- Johnson & Johnson
DePuy Synthes and Ethicon span orthopedics and surgery
- Medtronic
Medical-surgical scale in endoscopy, energy, and monitoring
- Smith & Nephew (ADR)
Sports medicine and orthopaedics peer with direct soft-tissue overlap
- Zimmer Biomet
Orthopedic reconstruction, S.E.T., and foot-and-ankle overlap
- Globus Medical
Musculoskeletal technology overlap in trauma and enabling systems
- Treace Medical Concepts
Focused foot-and-ankle competitor in bunion and midfoot repair
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CONMED | $45.59 | +2.01% | $1.34B | 24.1 | 10.2 | 1.0 | +0.3% |
| Stryker | $276.27 | +0.76% | $105.11B | 28.4 | 17.3 | 4.1 | +9.4% |
| Johnson & Johnson | $268.56 | −0.34% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| Medtronic | $91.27 | −0.52% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Smith & Nephew (ADR) | $27.47 | −0.81% | $11.63B | 19.0 | — | 1.8 | +4.6% |
| Zimmer Biomet | $94.16 | −0.17% | $18.25B | 22.9 | 10.7 | 2.1 | +4.8% |
| Globus Medical | $75.01 | +0.96% | $10.02B | 19.1 | 14.6 | 3.2 | +5.9% |
| Treace Medical Concepts | $4.60 | +2.68% | $290.6M | — | — | 1.4 | −4.2% |
| Median | 22.8 | 15.2 | 3.1 | +5.9% |